Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
M&A / Property Routine +

DiagnaMed Completes Acquisition of Colchester East Natural Hydrogen Project in Nova Scotia

DiagnaMed Consolidates Nova Scotia Footprint Amidst Ontario Discovery Correction

By The Northwire Desk — AI Analysis May 15, 2026 · 07:31 DMED · 0.07 Diagnamed Holdings Corp.
Executive Summary
  • DiagnaMed Holdings Corp. announced the closing of its acquisition of the Colchester East Natural Hydrogen Project in Nova Scotia on May 15, 2026.
  • The transaction involved $10,000 cash and issuance of 10,000,000 common shares at an issue price of $0.06 per share.
  • The property comprises 30 licenses totaling 2,104 claims in the Cumberland Basin.
  • Vendors received a 2.0% gross revenue royalty on hydrogen or minerals produced, with an option for DiagnaMed to buy back 50% of this royalty for $2,000,000.
  • Directors and officers were granted 7,000,000 options at $0.075 exercise price with a two-year term.
  • This closing follows the initial acquisition agreement announced on December 10, 2025.
Material Impact
  • The news represents the execution of a previously announced transaction (December 2025), meaning market expectations were already priced in during the prior announcement phase.
  • Asset expansion is positive as it adds 30 licenses to the portfolio, diversifying beyond the Ontario Temiscamingue Graben into Nova Scotia.
  • Dilution risk exists with 10 million shares issued; however, at $0.06 per share ($600k value), this is a relatively small capital outlay compared to typical exploration budgets.
  • The royalty burden (2%) creates a future revenue obligation but includes a buy-back option for $2M which mitigates long-term cost if production scales.
  • No new financial catalysts or revenue milestones are disclosed; the impact is incremental asset accumulation rather than fundamental value creation.
DMED · Price
Company Overview
  • DiagnaMed Holdings Corp. focuses on natural hydrogen exploration in Canada.
  • Flagship Project: Ontario Temiscamingue Graben Hydrogen Corridor.
  • Recent Discovery (Oct 2025): Confirmed widespread natural hydrogen system with soil-gas anomalies exceeding 500 ppm H2, peaking at 2,817 ppm.
  • Expansion: Acquisition of Colchester East Natural Hydrogen Project in Nova Scotia adds jurisdictional diversity to the portfolio.
  • Technology Focus: Utilizes soil-gas surveys and plans for drilling to evaluate commercial potential.
Read the original news release →

More from Diagnamed Holdings Corp.

Feb 23, 2026 · 13:00

SEDAR Interim Financial Statements

None Dec 10, 2025 · 16:55

Diagnamed enters deal to buy Colchester East project

M&A / Property Dec 10, 2025 · 07:03

DiagnaMed Enters Acquisition Agreement to Acquire Colchester East Natural Hydrogen Project in Nova Scotia

M&A / Property Oct 27, 2025 · 07:01

DiagnaMed and QIMC Confirm Major Expansion of Hydrogen Zone by Over 11 Kilometers in Ontario's Temiscamingue Graben

Production / Operations Oct 14, 2025 · 17:27

None

Drill Results Oct 14, 2025 · 07:03

DiagnaMed and QIMC Confirm Major Discovery of Widespread Natural Hydrogen System in Ontario's Temiscamingue Graben

Drill Results